Companies › Larimar Therapeutics
2 active drug programs in 2 registered trials: 1 Phase 2, 1 Phase 3; Neurology; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Nomlabofusp Recombinant human frataxin fusion protein | FXN | Phase 3 | Friedreich Ataxia | Jul 2029 |
| CTI-1601 Recombinant fusion protein delivering human frataxin | FXN | Phase 2 | Friedreich Ataxia | Jan 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06447025 | CTI-1601 | Phase 2 | Friedreich Ataxia | Neurology | Jan 2027 |
| NCT07778836 | Nomlabofusp | Phase 3 | Friedreich Ataxia | Neurology | Jul 2029 |
Cash and short-term investments of $156m on 2026-06-30; operating cash outflow about $180m a year; runway about 10 months at that burn, to May 2027; 1 of 2 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 5 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
IGC Pharma Biohaven Pharmaceuticals Annovis Bio Immunic Satellos Bioscience
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.